Palvella Therapeutics, Inc.
PVLA
$156.13
-$0.42-0.27%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 91.58% | 95.01% | 165.16% | 176.99% | 240.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 117.49% | 125.60% | 173.87% | 184.11% | 247.68% |
| Operating Income | -117.49% | -125.60% | -173.87% | -184.11% | -247.68% |
| Income Before Tax | -117.38% | -113.56% | -139.27% | -567.01% | -358.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -117.38% | -113.56% | -139.27% | -567.01% | -358.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -117.38% | -113.56% | -139.27% | -567.01% | -358.04% |
| EBIT | -117.49% | -125.60% | -173.87% | -184.11% | -247.68% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 25.49% | 48.57% | 58.39% | 47.92% | -88.55% |
| Normalized Basic EPS | 27.67% | 49.11% | 58.28% | 45.90% | -40.97% |
| EPS Diluted | 25.49% | 48.57% | 58.39% | 47.92% | -88.55% |
| Normalized Diluted EPS | 27.67% | 49.11% | 58.28% | 45.90% | -40.97% |
| Average Basic Shares Outstanding | 83.67% | 159.41% | 405.45% | 232.93% | 83.10% |
| Average Diluted Shares Outstanding | 83.67% | 159.41% | 405.45% | 232.93% | 83.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |